Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Neoplasm, Residual 1Leukemia 1Graft vs Host Disease 1

Interventions

blinatumomab 3Blood Specimen Collection 2Azacitidine 2venetoclax 1ivosidenib 1gilteritinib 1daratumumab 1avapritinib 1Transplantation 1Radiosurgery 1Neoadjuvant Therapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lenalidomide 1Interferon alpha-2 1Inotuzumab Ozogamicin 1Idarubicin 1High-Throughput Nucleotide Sequencing 1Daunorubicin 1Cytarabine 1Control Groups 1Consolidation Chemotherapy 1Chemotherapy, Adjuvant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neoplasm, Residual × Interferon alpha-2 × Clear all
NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡